Tests for the noninvasive diagnosis of kidney transplant rejection should be evaluated by kidney transplant programs

To the Editor: We welcome the availability and approval of tests designed for the noninvasive detection of the presence or absence of kidney transplant rejection. Currently, three such tests are commercially available: AlloSure by CareDx and Prospera by Natera detect donor-derived cell-free DNA (dd-cfDNA) in blood,1Bloom RD Bromberg JS Poggio ED et al.Cell-free DNA and active rejection in kidney allografts.J Am Soc Nephrol. 2017; 28:...